Life science companies — one of Massachusetts' key sectors — are coming off a week that showcased them at their strongest, according to local industry insiders who attended the JP Morgan Healthcare Conference in San Francisco.
More than 240 biotech companies — many of them from Massachusetts — made presentations to about 500 investors at last week's conference, said Donna LaVoie, president and CEO of the LaVoie Group, a Cambridge health-care communications company.
About 25 companies already are in line to go public, said Bruce Booth, a partner at Atlas Venture in Cambridge, and by the end of the year, the number likely will reach 30.
"There is a shift," said Ron Renaud Jr., president and CEO of Idenix Pharmaceuticals in Cambridge. "We used to talk about (only) 15 or 20 profitable biotechs."
Immuno-oncology companies — those that focus on getting the immune system to attack a cancer — are among the hottest, Booth said.
But not every investor is waiting for an IPO, he said; the pharmaceutical industry is embracing innovative new start-ups, wanting to get involved with them at the earliest stages.
"The discussion is about launching these great new drugs," Booth said. "Many of them were born in small biotechs."
The "build-to-buy" structured deal — one in which you create a company, already knowing who the buyer will be — is here to stay, he said.
"You know exactly what your return curve is." Booth said.
Anda sedang membaca artikel tentang
Local life science companies flex muscles at conference
Dengan url
http://terdiamtersipu.blogspot.com/2014/01/local-life-science-companies-flex.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Local life science companies flex muscles at conference
namun jangan lupa untuk meletakkan link
Local life science companies flex muscles at conference
sebagai sumbernya
0 komentar:
Posting Komentar